881 related articles for article (PubMed ID: 29566151)
21. Effects of Klebsiella pneumoniae carbapenemase subtypes, extended-spectrum β-lactamases, and porin mutations on the in vitro activity of ceftazidime-avibactam against carbapenem-resistant K. pneumoniae.
Shields RK; Clancy CJ; Hao B; Chen L; Press EG; Iovine NM; Kreiswirth BN; Nguyen MH
Antimicrob Agents Chemother; 2015 Sep; 59(9):5793-7. PubMed ID: 26169413
[TBL] [Abstract][Full Text] [Related]
22. Mutations in
Haidar G; Clancy CJ; Shields RK; Hao B; Cheng S; Nguyen MH
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28223379
[TBL] [Abstract][Full Text] [Related]
23. The Effect of β-Lactam Antibiotics on the Evolution of Ceftazidime/Avibactam and Cefiderocol Resistance in KPC-Producing Klebsiella pneumoniae.
Zhang P; Hu H; Shi Q; Sun L; Wu X; Hua X; McNally A; Jiang Y; Yu Y; Du X
Antimicrob Agents Chemother; 2023 Mar; 67(3):e0127922. PubMed ID: 36794957
[TBL] [Abstract][Full Text] [Related]
24. A Ceftazidime-Avibactam-Resistant and Carbapenem-Susceptible Klebsiella pneumoniae Strain Harboring
Niu S; Chavda KD; Wei J; Zou C; Marshall SH; Dhawan P; Wang D; Bonomo RA; Kreiswirth BN; Chen L
mSphere; 2020 Aug; 5(4):. PubMed ID: 32848008
[TBL] [Abstract][Full Text] [Related]
25. Ceftazidime-avibactam activity against a challenge set of carbapenem-resistant Enterobacterales: Ompk36 L3 alterations and β-lactamases with ceftazidime hydrolytic activity lead to elevated MIC values.
Castanheira M; Doyle TB; Hubler C; Sader HS; Mendes RE
Int J Antimicrob Agents; 2020 Jul; 56(1):106011. PubMed ID: 32417206
[TBL] [Abstract][Full Text] [Related]
26. Effects of KPC Variant and Porin Genotype on the
Wilson WR; Kline EG; Jones CE; Morder KT; Mettus RT; Doi Y; Nguyen MH; Clancy CJ; Shields RK
Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30617090
[TBL] [Abstract][Full Text] [Related]
27. Emergence of ceftazidime-avibactam resistance due to a novel blaKPC-2 mutation during treatment of carbapenem-resistant Klebsiella pneumoniae infections.
Liao Q; Deng J; Feng Y; Zhang W; Wu S; Liu Y; Che H; Xie Y
J Infect Public Health; 2022 May; 15(5):545-549. PubMed ID: 35461077
[TBL] [Abstract][Full Text] [Related]
28. Identifying Spectra of Activity and Therapeutic Niches for Ceftazidime-Avibactam and Imipenem-Relebactam against Carbapenem-Resistant Enterobacteriaceae.
Haidar G; Clancy CJ; Chen L; Samanta P; Shields RK; Kreiswirth BN; Nguyen MH
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630202
[TBL] [Abstract][Full Text] [Related]
29. High ceftazidime hydrolysis activity and porin OmpK35 deficiency contribute to the decreased susceptibility to ceftazidime/avibactam in KPC-producing Klebsiella pneumoniae.
Shen Z; Ding B; Ye M; Wang P; Bi Y; Wu S; Xu X; Guo Q; Wang M
J Antimicrob Chemother; 2017 Jul; 72(7):1930-1936. PubMed ID: 28333323
[TBL] [Abstract][Full Text] [Related]
30. Ceftazidime-Avibactam Resistance Associated with Increased
Coppi M; Di Pilato V; Monaco F; Giani T; Conaldi PG; Rossolini GM
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31964792
[TBL] [Abstract][Full Text] [Related]
31. Mutations in porin LamB contribute to ceftazidime-avibactam resistance in KPC-producing Klebsiella
Guo Y; Liu N; Lin Z; Ba X; Zhuo C; Li F; Wang J; Li Y; Yao L; Liu B; Xiao S; Jiang Y; Zhuo C
Emerg Microbes Infect; 2021 Dec; 10(1):2042-2051. PubMed ID: 34551677
[TBL] [Abstract][Full Text] [Related]
32. Analyses of a Ceftazidime-Avibactam-Resistant
Castanheira M; Arends SJR; Davis AP; Woosley LN; Bhalodi AA; MacVane SH
mSphere; 2018 Sep; 3(5):. PubMed ID: 30258039
[TBL] [Abstract][Full Text] [Related]
33. Acquisition of a Stable and Transferable
Huang J; Zhang S; Zhao Z; Chen M; Cao Y; Li B
Front Cell Infect Microbiol; 2021; 11():658070. PubMed ID: 34354959
[TBL] [Abstract][Full Text] [Related]
34. KPC-2 allelic variants in
Sanz MB; Pasteran F; de Mendieta JM; Brunetti F; Albornoz E; Rapoport M; Lucero C; Errecalde L; Nuñez MR; Monge R; Pennini M; Power P; Corso A; Gomez SA
Microbiol Spectr; 2024 Mar; 12(3):e0411123. PubMed ID: 38319084
[TBL] [Abstract][Full Text] [Related]
35. Molecular Mechanisms Driving the
Li X; Ke H; Wu W; Tu Y; Zhou H; Yu Y
mSphere; 2021 Dec; 6(6):e0085921. PubMed ID: 34935448
[TBL] [Abstract][Full Text] [Related]
36. Activity of Ceftazidime-Avibactam Against Clinical Isolates of Klebsiella pneumoniae, Including KPC-Carrying Isolates, Endemic to New York City.
Manning N; Balabanian G; Rose M; Landman D; Quale J
Microb Drug Resist; 2018; 24(1):35-39. PubMed ID: 28590820
[TBL] [Abstract][Full Text] [Related]
37. Klebsiella pneumoniae carbapenemase (KPC) producer resistant to ceftazidime-avibactam due to a deletion in the blaKPC3 gene.
Antinori E; Unali I; Bertoncelli A; Mazzariol A
Clin Microbiol Infect; 2020 Jul; 26(7):946.e1-946.e3. PubMed ID: 32061796
[TBL] [Abstract][Full Text] [Related]
38. Impact of Ceftazidime-Avibactam Treatment in the Emergence of Novel KPC Variants in the ST307-Klebsiella pneumoniae High-Risk Clone and Consequences for Their Routine Detection.
Hernández-García M; Castillo-Polo JA; Cordero DG; Pérez-Viso B; García-Castillo M; Saez de la Fuente J; Morosini MI; Cantón R; Ruiz-Garbajosa P
J Clin Microbiol; 2022 Mar; 60(3):e0224521. PubMed ID: 35107303
[TBL] [Abstract][Full Text] [Related]
39. In vitro activity of cefiderocol against ceftazidime-avibactam susceptible and resistant KPC-producing Enterobacterales: cross-resistance and synergistic effects.
Bianco G; Boattini M; Comini S; Iannaccone M; Bondi A; Cavallo R; Costa C
Eur J Clin Microbiol Infect Dis; 2022 Jan; 41(1):63-70. PubMed ID: 34462816
[TBL] [Abstract][Full Text] [Related]
40. Klebsiella pneumoniae carbapenemase (KPC) in urinary infection isolates.
Bedenić B; Sardelić S; Bogdanić M; Zarfel G; Beader N; Šuto S; Krilanović M; Vraneš J
Arch Microbiol; 2021 May; 203(4):1825-1831. PubMed ID: 33507339
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]